Supplementary Figure S3 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

• Responders showed distinct patterns in DDR gene mutations compared to non-responders, indicating potential for personalized treatment.
• The study highlights significant differences in treatment arms for DNA damage response gene alterations.
• Preoperative treatment with ipilimumab and nivolumab reveals important insights into therapeutic outcomes for urothelial cancer.
• Findings advocate for further investigation into the role of DDR genes in treatment dynamics and efficacy.

Abstract